This vaccine candidate is a new formulation with a modified adjuvant1, and a Japanese Phase 1/2 clinical trial started in
1. Substance that strengthens vaccine efficacy by immune activation
2. This research was supported by
The Phase 2/3 clinical trial that began in October (jRCT No.: 2031210383) is a open-label study. The safety and immunogenicity of two doses of the vaccine will be assessed and then we will confirm clinical benefit. In parallel with this clinical trial, we will prepare for the implementation of multiple clinical trials globally.We will continue to consult closely with the
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contact:
E: contact@shionogi.eu
Tel: +44 (0)20 3053 4190
German language
E: kontakt@shionogi.eu
Tel: +49 (0)89 2109 3049
(C) 2021 Electronic News Publishing, source